Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects
Condition: Alzheimer's Disease Intervention: Drug: F-18 PMPBB3 Sponsor: Chang Gung Memorial Hospital Recruiting
Authors: Silverstein NM, Pitheckoff N, Dugan E Abstract Engaging gerontology students in research that hits "close-to-home" can have lasting benefits for them and their communities both professionally and personally. Since 2016, cohorts of undergraduate/certificate students in an online applied research in aging course have explored healthy aging in their Massachusetts' (MA) communities. The students utilized both primary and secondary data sources. First, they extracted data from the 2014-2015 healthy aging data report (HADR) community profiles of 367 MA communities. Then they conducted in-person in...
AbstractPreclinical experiments and clinical trials demonstrated that angiotensin II AT1 receptor overactivity associates with aging and cellular senescence and that AT1 receptor blockers (ARBs) protect from age-related brain disorders. In a primary neuronal culture submitted to glutamate excitotoxicity, gene set enrichment analysis (GSEA) revealed expression of several hundred genes altered by glutamate and normalized by candesartan correlated with changes in expression in Alzheimer ’s patient’s hippocampus. To further establish whether our data correlated with gene expression alterations associated with aging...
Low-dose hydromethylthionine may help prevent both cognitive decline and brain atrophy in early Alzheimer's disease, new exploratory research suggests.Medscape Medical News
Conclusion: The evidence from the present study suggests that T allele of CD33 rs3865444 polymorphism is associated with LOAD in the studied Iranian population. PMID: 31799158 [PubMed]
Spain's Grifols said on Friday the latest results from a clinical trial of its Alzheimer's treatment show positive effects by achieving a reduction of the disease's progression in patients with mild and moderate conditions.
Incidence varied considerably by region, ranging from 0 to more than 3 percent across population areas in 2014
CONCLUSION: We demonstrated that EVOO therapy may prevent the risk of patients with MCI to progress to AD via decreasing fibrinolytic factors PAI-1 and a2 antiplasmin that reflecting in the diminution of the hallmarks proteins of AD, tau and Aβ amyloid as well and in a biomarker of oxidative stress, MDA. PMID: 31802059 [PubMed - in process]
CONCLUSION: The low agreement between amyloid PET/CT and previous clinical and instrumental assessments that we found in our study suggests that the amyloid PET/CT provides additional and early information. To perform an early and differential diagnosis of AD could have a great impact on the patient's management and cost of care in order to perform the correct therapeutic interventions and to allow family members to manage adequately the patient's demanding care. PMID: 31802055 [PubMed - in process]